OncoZenge
4,15
SEK
+3,75 %
ONCOZ
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 investor følger denne virksomhed
+3,75%
-59,79%
-31,86%
+18,4%
+34,3%
+18,57%
-60,1%
-
-66,09%
oncozenge.se/investerare
OncoZenge is a Swedish pharmaceutical company that develops treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. After completing phase 2 studies, the company's product candidate is under further development as a basis for applying for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
ONCOZ
Daglig lav / høj pris
3,85 / 4,16
SEK
Markedsværdi
48,61 mio. SEK
Aktieomsætning
184,59 t SEK
Volumen
46 t
Finanskalender
Årsrapport
20.02.2025
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| Niclas Holmgren | 11,8 % | 11,8 % |
| Linc AB | 10,0 % | 10,0 % |
| Ozbek, Andreas | 8,4 % | 8,4 % |
| Östersjöstiftelsen | 4,9 % | 4,9 % |
| Avanza Pension | 4,8 % | 4,8 % |
| Kalle Holmgren | 3,4 % | 3,4 % |
| Nordnet Pensionsförsäkring AB | 3,2 % | 3,2 % |
| Kildal, Stian | 2,6 % | 2,6 % |
| Jimmy Olsson | 2,5 % | 2,5 % |
| Joacim Mansolahti Friberg | 2,0 % | 2,0 % |
ViserAlle indholdstyper
Redeye: OncoZenge Q3 2024 - Approaching lift-off
Redeye: Redeye Initiates Coverage of OncoZenge
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools